- Report
- October 2024
- 260 Pages
Global
From €2524EUR$2,655USD£2,120GBP
- Report
- November 2023
- 272 Pages
Global
From €3394EUR$3,570USD£2,851GBP
- Report
- May 2023
- 458 Pages
Global
From €3394EUR$3,570USD£2,851GBP
- Report
- February 2022
- 258 Pages
Global
From €3529EUR$3,712USD£2,965GBP
- Book
- June 2024
- 496 Pages
- Book
- May 2021
- 512 Pages
- Book
- November 2019
- 432 Pages
- Book
- November 2019
- 432 Pages
- Book
- April 2024
- 448 Pages
- Book
- January 2019
- 264 Pages
- Book
- January 2017
- 488 Pages
- Book
- January 2016
- 952 Pages
- Book
- May 2014
- 560 Pages
- Book
- April 2014
- 344 Pages
- Book
- April 2013
- 296 Pages
- Book
- November 2012
- 240 Pages
- Book
- July 2022
North America
- Book
- May 2019
North America

Hemophilia is a rare, inherited bleeding disorder in which the blood does not clot properly. People with hemophilia lack certain proteins, called clotting factors, which are necessary for normal blood clotting. Without these clotting factors, even a minor injury can cause excessive bleeding. Hemophilia is classified into two main types, hemophilia A and hemophilia B, depending on the clotting factor that is missing.
The hemophilia market is a subset of the hematology market, which includes treatments for a variety of blood-related disorders. The hemophilia market is composed of treatments for hemophilia A and B, such as recombinant clotting factors, gene therapy, and other treatments. These treatments are used to reduce the frequency and severity of bleeding episodes, as well as to prevent bleeding in the first place.
Some companies in the hemophilia market include Novo Nordisk, Pfizer, Shire, Bayer, and CSL Behring. Show Less Read more